Tela Bio, Inc. (TELA) — 8-K Filings

8-K Filings (19)

• TELA Bio Files 8-K on Financials — Nov 13, 2025 Risk: low
  On November 13, 2025, TELA Bio, Inc. filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition, along with
• 8-K Filing — Nov 3, 2025
• TELA Bio Appoints New Directors, Adjusts Executive Pay — Oct 9, 2025 Risk: medium
  TELA Bio, Inc. announced on October 4, 2025, changes in its board of directors and executive compensation. Specifically, the company elected two new directors,
• TELA Bio Files 8-K on Operations and Financials — Aug 11, 2025 Risk: low
  On August 11, 2025, TELA Bio, Inc. filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition, along with Re
• TELA Bio Appoints New CFO, Kevin J. O'Malley — Jun 2, 2025 Risk: medium
  On May 30, 2025, TELA Bio, Inc. announced the appointment of Kevin J. O'Malley as its new Chief Financial Officer, effective June 3, 2025. O'Malley will receive
• TELA Bio Reports Board Changes and Shareholder Votes — May 30, 2025 Risk: medium
  TELA Bio, Inc. announced on May 28, 2025, changes in its board of directors and executive compensation arrangements. The filing also details the submission of m
• TELA Bio Files 8-K on Financials and Operations — May 8, 2025 Risk: low
  TELA Bio, Inc. filed an 8-K on May 8, 2025, reporting on its results of operations and financial condition. The filing also includes information related to Regu
• TELA Bio Files 8-K — Mar 31, 2025 Risk: low
  TELA Bio, Inc. filed an 8-K on March 31, 2025, reporting other events and financial statements. The filing does not contain specific financial figures or materi
• TELA Bio Files 8-K on Financials — Mar 20, 2025 Risk: low
  On March 20, 2025, TELA Bio, Inc. filed an 8-K report detailing its financial condition and results of operations. The filing also included disclosures related
• TELA Bio, Inc. Files 8-K Report — Nov 7, 2024 Risk: medium
  On November 7, 2024, TELA Bio, Inc. filed an 8-K report detailing its financial results and other relevant information. The filing includes information on the c
• TELA Bio Files 8-K: Material Agreement & Financials — Oct 23, 2024 Risk: low
  On October 23, 2024, TELA Bio, Inc. filed an 8-K report. The filing primarily concerns the entry into a material definitive agreement and the inclusion of finan
• TELA Bio Files 8-K on Operations and Reg FD — Oct 22, 2024 Risk: low
  TELA Bio, Inc. filed an 8-K on October 22, 2024, to report on its results of operations and financial condition, as well as a Regulation FD disclosure. The fili
• TELA Bio Files 8-K on Financials and Operations — Aug 12, 2024 Risk: low
  TELA Bio, Inc. filed an 8-K on August 12, 2024, reporting on its results of operations and financial condition. The filing also includes disclosures related to
• TELA Bio Appoints New CFO, Elects Directors — Jun 6, 2024 Risk: low
  On June 4, 2024, TELA Bio, Inc. filed an 8-K report detailing several key events. The company announced the election of two new directors, Dr. David J. McVay an
• TELA Bio Closes $34.5M Public Offering — May 20, 2024 Risk: medium
  On May 19, 2024, TELA Bio, Inc. filed an 8-K report to announce the closing of its previously announced underwritten public offering. The company successfully r
• TELA Bio Files 8-K for Operations and Financials — May 9, 2024 Risk: low
  TELA Bio, Inc. filed an 8-K on May 9, 2024, to report on its results of operations and financial condition, as well as to provide a Regulation FD disclosure and
• TELA Bio, Inc. Files 8-K Report — Apr 15, 2024 Risk: low
  On April 15, 2024, TELA Bio, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, indicating updates or disclosures relate
• TELA Bio, Inc. Files 8-K on Financials and Operations — Mar 21, 2024 Risk: low
  On March 21, 2024, TELA Bio, Inc. filed an 8-K report detailing its financial condition and results of operations. The filing also includes disclosures related
• TELA Bio CFO Resigns, Secures $50M Credit Facility — Mar 20, 2024 Risk: medium
  On March 15, 2024, TELA Bio, Inc. filed an 8-K report detailing the resignation of its Chief Financial Officer, Adrian Jones, effective March 15, 2024. The comp

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX